Equities

HitGen Inc

688222:SHH

HitGen Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)8.50
  • Today's Change-0.150 / -1.73%
  • Shares traded2.86m
  • 1 Year change-42.61%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

HitGen Inc is a China-based company mainly engaged in the early research and development of original innovative drugs. The Company focuses on the research and creation of deoxyribonucleic acid encoded compound library (DEL) technology, research and development of hit compounds and lead compounds. The Company mainly provides DEL screening services, DEL library customization services, chemical synthesis services and transfer of new drug research and development projects. The Company conducts its businesses within the domestic market and to overseas markets.

  • Revenue in CNY (TTM)410.39m
  • Net income in CNY45.10m
  • Incorporated2012
  • Employees452.00
  • Location
    HitGen IncBlock 6,No.8 Huigu East 1st Road, Tianfu InternaCHENGDU 610200ChinaCHN
  • Phone+86 2 885197385
  • Fax+86 2 883310298
  • Websitehttps://www.hitgen.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Qingdao Vland Biotech INC1.26bn78.59m2.65bn1.57k33.631.55--2.100.31160.31165.016.770.4323.494.07804,705.903.705.785.787.8945.4146.138.5710.340.868722.880.312733.593.078.0515.56-0.650724.68-6.89
Bide Pharmatech Co Ltd1.10bn77.60m2.72bn846.0034.511.38--2.470.86690.866912.2521.730.46871.024.831,301,939.003.26--3.73--38.92--6.96--5.04--0.043--30.94---24.94------
Shanghai Aladdin Biochemical Tech Co Ltd455.90m102.18m2.78bn566.0022.812.71--6.100.43970.43971.823.700.28660.35988.66805,473.806.798.837.819.6161.3461.4923.7026.853.13--0.272945.716.5519.36-7.489.9531.41--
Jiangsu Yahong Meditech Co Ltd94.17m-398.99m2.90bn394.00--1.32--30.81-0.6969-0.69690.16453.850.036611.125.92239,007.60-15.55-15.80-16.49-16.4877.8555.32-424.48-9,445.9110.12--0.0711--52,594.79---62.42--64.28--
Hinova Pharmaceuticals Inc109.74k-229.37m3.16bn179.00--2.47--28,818.65-2.32-2.320.001112.920.000077.250.0054613.07-14.92-31.86-16.50-37.18-400.96---209,012.60-25,578.247.21--0.036---100.00--2.44--124.37--
Shanghai Medicilon Inc1.01bn-269.57m3.34bn2.42k--1.37--3.29-2.01-2.017.6818.050.3656.191.32390,279.00-9.709.34-12.4911.731.8136.71-26.5714.932.87--0.092320.18-17.6833.26-109.82--23.60--
Beijing Kawin Technol Sha-hld Co Ltd1.44bn120.57m3.35bn584.0027.251.87--2.330.71920.71928.5610.480.62541.583.702,465,474.006.485.318.226.7683.0286.0210.368.103.22--0.10343.8221.7314.8739.7121.0425.01--
Beijing Sun-Novo Pharma Research Co Ltd1.03bn215.33m3.38bn1.39k15.683.10--3.271.921.929.239.730.591932.801.65754,698.2011.7312.9918.6521.7056.0653.9319.8221.341.9835.780.306510.7437.7647.2218.0854.9034.77--
HitGen Inc410.39m45.10m3.47bn452.0076.602.56--8.450.11290.11291.033.380.24187.225.05907,947.102.604.632.765.1049.2058.8910.7720.6616.5324.490.143119.1412.6419.6961.16-1.96-6.12--
InventisBio Co Ltd120.40m-330.44m4.42bn221.00--2.43--36.74-0.5746-0.57460.20873.150.0576--0.9217544,796.80-15.82---16.90--94.63---274.46------0.0038------41.26------
GemPharmatech Co Ltd666.71m157.68m4.60bn1.51k28.842.17--6.910.38940.38941.645.170.26594.562.21442,699.506.299.457.3011.1365.1870.2123.6528.163.96--0.068914.6820.4563.48-3.48--141.38--
Data as of Sep 20 2024. Currency figures normalised to HitGen Inc's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

2.19%Per cent of shares held by top holders
HolderShares% Held
Gfund Management Co., Ltd.as of 31 Dec 20232.46m0.62%
Da Cheng Fund Management Co., Ltd.as of 31 Dec 20232.43m0.61%
Wanjia Asset Management Co., Ltd.as of 31 Dec 20231.10m0.28%
China Universal Asset Management Co., Ltd.as of 31 Dec 2023731.05k0.18%
Changsheng Fund Management Co., Ltd.as of 31 Dec 2023692.57k0.17%
China Merchants Fund Management Co., Ltd.as of 31 Dec 2023595.42k0.15%
E Fund Management Co., Ltd.as of 30 Jun 2024375.91k0.09%
BlackRock Advisors LLCas of 31 Jul 2024179.45k0.05%
Xinyuan Asset Management Co., Ltd.as of 31 Dec 2023114.70k0.03%
SSgA Funds Management, Inc.as of 05 Sep 2024101.69k0.03%
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.